vs
Apellis Pharmaceuticals, Inc.（APLS）与Zeta Global Holdings Corp.（ZETA）财务数据对比。点击上方公司名可切换其他公司
Zeta Global Holdings Corp.的季度营收约是Apellis Pharmaceuticals, Inc.的2.0倍（$394.6M vs $199.9M），Zeta Global Holdings Corp.净利率更高（1.7% vs -29.5%，领先31.1%），Zeta Global Holdings Corp.同比增速更快（25.4% vs -5.9%），Zeta Global Holdings Corp.自由现金流更多（$60.9M vs $-14.3M），过去两年Zeta Global Holdings Corp.的营收复合增速更高（42.3% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Zeta Global Holdings Corp是一家2007年成立的美国营销科技企业，为各公司提供多渠道营销工具矩阵，核心业务围绕客户关系的构建、维护与价值变现展开。该公司于2021年6月10日在纽约证券交易所上市，上市时估值达17亿美元。
APLS vs ZETA — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $394.6M |
| 净利润 | $-59.0M | $6.5M |
| 毛利率 | — | 59.5% |
| 营业利润率 | -25.6% | 4.5% |
| 净利率 | -29.5% | 1.7% |
| 营收同比 | -5.9% | 25.4% |
| 净利润同比 | -62.2% | -57.1% |
| 每股收益（稀释后） | $-0.40 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $394.6M | ||
| Q3 25 | $458.6M | $337.2M | ||
| Q2 25 | $178.5M | $308.4M | ||
| Q1 25 | $166.8M | $264.4M | ||
| Q4 24 | $212.5M | $314.7M | ||
| Q3 24 | $196.8M | $268.3M | ||
| Q2 24 | $199.7M | $227.8M | ||
| Q1 24 | $172.3M | $194.9M |
| Q4 25 | $-59.0M | $6.5M | ||
| Q3 25 | $215.7M | $-3.6M | ||
| Q2 25 | $-42.2M | $-12.8M | ||
| Q1 25 | $-92.2M | $-21.6M | ||
| Q4 24 | $-36.4M | $15.2M | ||
| Q3 24 | $-57.4M | $-17.4M | ||
| Q2 24 | $-37.7M | $-28.1M | ||
| Q1 24 | $-66.4M | $-39.6M |
| Q4 25 | — | 59.5% | ||
| Q3 25 | — | 60.5% | ||
| Q2 25 | — | 62.1% | ||
| Q1 25 | — | 60.9% | ||
| Q4 24 | — | 60.0% | ||
| Q3 24 | — | 60.6% | ||
| Q2 24 | — | 60.0% | ||
| Q1 24 | — | 60.6% |
| Q4 25 | -25.6% | 4.5% | ||
| Q3 25 | 48.7% | 2.6% | ||
| Q2 25 | -18.6% | -1.7% | ||
| Q1 25 | -50.0% | -6.1% | ||
| Q4 24 | -12.3% | 2.2% | ||
| Q3 24 | -24.0% | -4.6% | ||
| Q2 24 | -14.7% | -11.7% | ||
| Q1 24 | -36.0% | -18.4% |
| Q4 25 | -29.5% | 1.7% | ||
| Q3 25 | 47.0% | -1.1% | ||
| Q2 25 | -23.6% | -4.2% | ||
| Q1 25 | -55.3% | -8.2% | ||
| Q4 24 | -17.1% | 4.8% | ||
| Q3 24 | -29.2% | -6.5% | ||
| Q2 24 | -18.9% | -12.3% | ||
| Q1 24 | -38.5% | -20.3% |
| Q4 25 | $-0.40 | $0.04 | ||
| Q3 25 | $1.67 | $-0.02 | ||
| Q2 25 | $-0.33 | $-0.06 | ||
| Q1 25 | $-0.74 | $-0.10 | ||
| Q4 24 | $-0.30 | $0.10 | ||
| Q3 24 | $-0.46 | $-0.09 | ||
| Q2 24 | $-0.30 | $-0.16 | ||
| Q1 24 | $-0.54 | $-0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $319.8M |
| 总债务越低越好 | — | $197.1M |
| 股东权益账面价值 | $370.1M | $804.6M |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.24× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $319.8M | ||
| Q3 25 | $479.2M | $385.2M | ||
| Q2 25 | $370.0M | $365.3M | ||
| Q1 25 | $358.4M | $364.4M | ||
| Q4 24 | $411.3M | $366.2M | ||
| Q3 24 | $396.9M | $418.5M | ||
| Q2 24 | $360.1M | $154.7M | ||
| Q1 24 | $325.9M | $141.6M |
| Q4 25 | — | $197.1M | ||
| Q3 25 | — | $196.9M | ||
| Q2 25 | — | $196.7M | ||
| Q1 25 | — | $196.5M | ||
| Q4 24 | — | $196.3M | ||
| Q3 24 | — | $196.1M | ||
| Q2 24 | — | $184.4M | ||
| Q1 24 | $93.1M | $184.2M |
| Q4 25 | $370.1M | $804.6M | ||
| Q3 25 | $401.2M | $689.2M | ||
| Q2 25 | $156.3M | $673.3M | ||
| Q1 25 | $164.2M | $676.6M | ||
| Q4 24 | $228.5M | $676.8M | ||
| Q3 24 | $237.1M | $474.9M | ||
| Q2 24 | $264.3M | $217.0M | ||
| Q1 24 | $266.7M | $191.6M |
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $821.4M | $1.1B | ||
| Q1 25 | $807.3M | $1.1B | ||
| Q4 24 | $885.1M | $1.1B | ||
| Q3 24 | $901.9M | $869.1M | ||
| Q2 24 | $904.5M | $583.9M | ||
| Q1 24 | $831.9M | $550.3M |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 0.41× | ||
| Q2 24 | — | 0.85× | ||
| Q1 24 | 0.35× | 0.96× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $64.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $60.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 15.4% |
| 资本支出强度资本支出/营收 | 0.1% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 9.81× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $185.1M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $64.1M | ||
| Q3 25 | $108.5M | $57.9M | ||
| Q2 25 | $4.4M | $42.0M | ||
| Q1 25 | $-53.4M | $34.8M | ||
| Q4 24 | $19.4M | $43.7M | ||
| Q3 24 | $34.1M | $34.4M | ||
| Q2 24 | $-8.3M | $31.1M | ||
| Q1 24 | $-133.0M | $24.7M |
| Q4 25 | $-14.3M | $60.9M | ||
| Q3 25 | $108.3M | $52.4M | ||
| Q2 25 | $4.4M | $39.7M | ||
| Q1 25 | $-53.4M | $32.1M | ||
| Q4 24 | $19.3M | $35.4M | ||
| Q3 24 | — | $29.5M | ||
| Q2 24 | $-8.4M | $24.4M | ||
| Q1 24 | $-133.3M | $18.9M |
| Q4 25 | -7.1% | 15.4% | ||
| Q3 25 | 23.6% | 15.6% | ||
| Q2 25 | 2.5% | 12.9% | ||
| Q1 25 | -32.0% | 12.1% | ||
| Q4 24 | 9.1% | 11.3% | ||
| Q3 24 | — | 11.0% | ||
| Q2 24 | -4.2% | 10.7% | ||
| Q1 24 | -77.3% | 9.7% |
| Q4 25 | 0.1% | 0.8% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | 2.6% | ||
| Q3 24 | 0.0% | 1.8% | ||
| Q2 24 | 0.0% | 3.0% | ||
| Q1 24 | 0.2% | 3.0% |
| Q4 25 | — | 9.81× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.87× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ZETA
暂无分部数据
